Rashmita Sahoo

Fakir Mohan University — India

Medicine · Health Sciences

13h-index662citations55works3.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(22), Lung Cancer Treatments and Mutations(21), Advanced Breast Cancer Therapies(14), Monoclonal and Polyclonal Antibodies Research(5), SARS-CoV-2 detection and testing(3)

Publications55 total

Enhancing Cybersecurity Awareness through Training and Educational Programs for Schools and Colleges in Remuna Tehsil, Balasore District, Odisha
International Journal of Integrative Research·2025Open Access
EMPOWERING COMPASSION: A SYSTEMATIC REVIEW OF PALLIATIVE CARE EDUCATION & TRAINING PROGRAM OUTCOMES FOR NURSING PROFESSIONALS
JOURNAL OF MECHANICS OF CONTINUA AND MATHEMATICAL SCIENCES·2025Open Access
PNF-Augumented Balance Training Using Balance Beam and Balance Board: A Controlled Trial Assessing Walking Speed Outcomes in Stroke Patients
Annals of Physiotherapy & Occupational Therapy·2025Open Access
The Effect of Frenkel's Exercise with PNF on Functional Reach in Stroke Survivors: A Randomized Control Trial
Annals of Physiotherapy & Occupational Therapy·2025Open Access
Assessment of the impact of a personalised nutrition intervention in impaired glucose regulation over 26 weeks: a randomised controlled trial
Scientific Reports·2024· 18 citedOpen Access
Supplementary Table 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Data from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Data from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Alexandra Léary(17), Abigail Evans(17), Stephen Johnston(17), Roger A’Hern(17), Judith M. Bliss(17), Simone Detre(17), Catherine Harper‐Wynne(17), Nigel Bundred(17), Gill Coombes(17), Mitch Dowsett(17), Benjamin P. Haynes(16), Margaret Hills(16), Ian Smith(16), Eswarachary Venkataswamy(9), Vidya V. Harini(7), V. Chitti Babu(7), Smitha Rao(7), Geeta V. Patil(7), Ashwini Nargund(6), Gopal Krishna Dhondalay(6)